Pre-market Hot Trades in US Stocks
Intchains pre-market down 17.86%. Based on recent key news:
<ol>
<li>
On April 17, Intchains announced its Ethereum staking scale and AI-driven operational transformation plan. The company disclosed that it has staked 8,040 ETH and plans to enhance operational efficiency through AI while reducing staff to save costs. This news raised market concerns about its future profitability, leading to a decline in stock price.
</li>
<li>
On April 17, the company's management stated that it would focus on core mining machine technology and Ethereum asset strategy, combining AI to enhance R&amp;D and operational efficiency. This strategic adjustment was interpreted by the market as a positive signal for future technological development, but it may increase operational risks in the short term, affecting stock price.
</li>
<li>
On April 17, Intchains plans to launch a new generation of mining machine products in the second half of 2026. The market's expectations and uncertainties regarding the new products have led to stock price fluctuations. The volatility in the cryptocurrency market has intensified, necessitating attention to risks.
</li>
</ol>
AleAnna pre-market up 17.03%. Based on recent key news:
<ol>
<li>
On April 17, AleAnna released a Form 3 document regarding the shareholding of company executives, showing the initial shareholding situation of Chief Accounting Officer Manfredo Bucciol. This information was made public through the EDGAR system, potentially raising market attention on the company's governance structure, driving stock price up.
</li>
<li>
On April 13, AleAnna appointed Manfredo Bucciol as Chief Accounting Officer, who has over 15 years of experience in accounting, auditing, and SEC reporting. This appointment may have enhanced market confidence in the company's financial management capabilities, further driving stock price up.
</li>
<li>
On April 17, AleAnna released relevant announcements through the EDGAR system, emphasizing changes in the company's financial and management aspects, attracting investor attention and leading to a significant increase in stock price. Recent market volatility has intensified, necessitating attention to risks.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Psyence Biomedical pre-market up 112.24%. Based on recent key news:
<ol>
<li>
On April 17, Psyence Biomedical announced that its pharmaceutical-grade psychedelic drug NPX-5 is being used in clinical trials. The company's CEO stated that this expansion marks a significant advancement in clinical infrastructure, supporting ongoing patient dosing. This news drove the stock price up by 69.85%.
</li>
<li>
On April 18, US President Trump signed an executive order to accelerate the accessibility of medical research and treatment based on psychedelic drugs. This move aims to assist veterans suffering from severe mental illnesses, further pushing the stock price up.
</li>
<li>
On April 17, Psyence Biomedical's API development department received federal licensing to support global distribution and clinical projects. This news caused the stock price to rise by 40.72%. The acceleration of psychedelic drug research and clear policy support are evident
Clearmind Medicine pre-market rose 66.76%. Based on recent key news:
</li>
<li>
On April 19, U.S. President Trump signed an executive order to accelerate the research and approval process for psychedelic therapies, focusing on drugs like ibogaine for the treatment of post-traumatic stress disorder, depression, and addiction. This move is expected to boost market demand for related drugs, leading to a significant increase in Clearmind Medicine's stock price.
</li>
<li>
On April 18, U.S. President Trump announced reforms aimed at speeding up the approval of medical research and treatments based on psychedelic drugs. This will directly affect the drug approval speed for Clearmind Medicine, enhancing market expectations and driving up the stock price. Favorable policies in the field of mental illness treatment have improved market expectations.
</li>
</ol>
Theriva Biologics pre-market rose 56.18%. Based on recent key news:
<ol>
<li>
On April 17, Theriva Biologics announced that it will present additional data from its VIRAGE Phase 2B clinical trial at the AACR 2026 Annual Meeting. This trial involves the application of VCN-01 in metastatic pancreatic cancer, demonstrating its potential to improve overall survival and progression-free survival. This news has driven up the stock price.
</li>
<li>
On April 17, the company plans to conduct a low-dose study to test whether more frequent and extended VCN-01 administration can further improve outcomes. This plan shows the company's confidence in its product, further boosting market sentiment.
</li>
<li>
On April 17, posters released by Theriva Biologics indicated that when VCN-01 is used in combination with gemcitabine/paclitaxel albumin-bound, both overall survival and progression-free survival improved for patients. This result has strengthened investor confidence in the company's products, driving up the stock price. The biotechnology industry has been active recently, with investors focusing on the progress of new therapies
</li>
</ol>

ANNA

Intchains pre-market down 17.86%; AleAnna pre-market up 17.03%; Psyence Biomedical pre-market up 112.24%; Clearmind Medicine pre-market up 66.76%; Theriva Biologics pre-market up 56.18%

Pre-market hot trades in US stocks: Intchains fell 17.86% in pre-market; AleAnna rose 17.03% in pre-market